CV9202 (also called BI1361849) is an active cancer immunotherapeutic comprising protamine-formulated, sequence-optimized mRNA encoding six NSCLC-associated antigens (NY-ESO-1, MAGE-C1, MAGE-C2, survivin, 5T4, and MUC-1). This evidence concerns the gene MAGEC1 and non-small cell lung carcinoma.